Business
StockNewsNow.com Publishes New SNNLive Video Interview with Aeolus Pharmaceuticals, Inc. Discussing Clinical Development and Milestones for 2016-2017
StockNewsNow.com Publishes New SNNLive Video Interview with Aeolus Pharmaceuticals, Inc. Discussing Clinical Development and Milestones for 2016-2017.
About this update from Aeolus Pharmaceuticals Inc
[{"type":"text","content":"\n\n\n\nStockNewsNow.com Publishes New SNNLive Video Interview with Aeolus Pharmaceuticals, Inc. Discussing Clinical Development and Milestones for 2016-2017\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nStockNewsNow.com Publishes New SNNLive Video Interview with Aeolus Pharmaceuticals, Inc. Discussing Clinical Development and Milestones for 2016-2017\nPR Newswire\nLOS ANGELES, July 7, 2016\n\n\n\nLOS ANGELES, July 7, 2016 /PRNewswire/ -- StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with David Cavalier, Chairman & CFO of Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection, according to the Company's website (see here: www.AOLSRX.com).  The video interview was recorded on Tuesday, June 7th, 2016 at the LD Micro Invitational in Bel Air, CA.\n\nClick the following link to watch the SNNLive Video Interview on StockNewsNow.com:\n\nUpdate with Aeolus Pharmaceuticals, Inc. – Biodefense and Biotechnology Company Discusses Clinical Development and Milestones for 2016-2017\n\nYou can follow Stock News Now on FACEBOOK, TWITTER, LINKEDIN, YOUTUBE, and STOCKTWITS\n\nPlease review important disclosures on our website at: http://stocknewsnow.com/legal.php#disclaimer\n\nAbout Aeolus Pharmaceuticals\n\nAeolus Pharmaceuticals is developing a platform of novel compounds, known as metalloporphyrins, for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Its lead compound, AEOL 10150, is being developed, with funding from the US Department of Health and Human Services, as a MCM against chemical and radiological weapons, where its initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure. Aeolus' strategy is to leverage the substantial investment in toxicology, manufacturing, and preclinical and clinical studies made by US Government agencies in AEOL 10150 to develop th...